FMC63-mCAR-T

FMC63-mCAR-T is an experimental hybrid chimeric antigen receptor (CAR) T-cell therapy developed for preclinical research in immunocompetent mouse models. It utilizes the FMC63 single-chain variable fragment (scFv)—the same antigen-binding domain found in all four FDA-approved human CD19-targeted CAR-T products (tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, and lisocabtagene maraleucel)—fused to murine signaling components. These components typically include the mouse CD8 hinge and transmembrane domains, the CD28 costimulatory domain, and the CD3ζ intracellular signaling domain. This hybrid design allows researchers to evaluate CAR-T cell expansion, persistence, and therapeutic strategies, such as amphiphilic vaccine (amph-vax) boosting, within syngeneic mouse models of B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma, providing a more physiologically relevant immune environment than immunodeficient models.

Other names

FMC63-mCARFMC-63-mCARFMC 63-mCARFMC63-murine-CAR-TFMC-63-murine-CAR-TFMC 63-murine-CAR-T